SCHEMBL24468262

SCHEMBL24468262

CC(C)(C)CNCc1ccc(C(F)(F)F)cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.46
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
PDE2A O00408 1/20 0.43
TRPV3 Q8NET8 3/20 0.41
KMT2A Q03164 1/20 0.39
DAO P14920 1/20 0.39
CNR1 P21554 2/20 0.37
CNR2 P34972 1/20 0.37
MBOAT4 Q96T53 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.35
GLS O94925 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
PPARG P37231 1/20 0.34
PPARD Q03181 1/20 0.34
PPARA Q07869 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30841845 0.87 KDM1A (0.48) KDM1AMAOAMAOBNPC1RAB9A
SCHEMBL24468397 0.87 KDM1A (0.48) KDM1AMAOAMAOBNPC1RAB9A
SCHEMBL10288360 0.83 KDM1A (0.48) KDM1AMAOAMAOBNPC1RAB9A
SCHEMBL30471983 0.83 KDM1A (0.48) KDM1AMAOAMAOBNPC1RAB9A
SCHEMBL10254379 0.81 KDM1A (0.49) KDM1AMAOAMAOBNPC1RAB9A
SCHEMBL24258303 0.81 KDM1A (0.46) KDM1AMAOAMAOBNPC1RAB9A
SCHEMBL30481847 0.81 KDM1A (0.46) KDM1AMAOAMAOBNPC1RAB9A
SCHEMBL10278513 0.80 KDM1A (0.50) KDM1AMAOAMAOBNPC1RAB9A
SCHEMBL23757911 0.79 KDM1A (0.45) KDM1AMAOAMAOBNPC1RAB9A
SCHEMBL29685743 0.79 KDM1A (0.45) KDM1AMAOAMAOBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4251624-B1 TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS AMGEN INC (US) 2025-10-29 EP disclosed
US-20240101570-A1 TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS AMGEN INC. 2024-03-28 US disclosed
WO-2022115377-A1 TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS AMGEN INC. (US) 2022-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101570-A1 TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 KDM1A 37/4885MAOA 3279/4885MAOB 3113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.